Press release
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022Third quarter 2023 Dupixent® global net sales (recorded by Sanofi)
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022Third quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $3.10 billion versus third quarter 2022Third quarter 2023 U.S. net sales for EYLEA® and EYLEA HD were $1.49 billion, including $43 million from EYLEA HDThird quarter 2023 Libtayo® global net sales increased 62% to $232 million versus third quarter 2022Third quarter 2023 GAAP diluted EPS of $8.89 and non-GAAP diluted EPS(a) of $11.59; includes unfavorable $0.77 impact from acquired IPR&D chargeFDA approved EYLEA HD for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) and Veopoz™ for CHAPLE diseaseTwo-year results reported for EYLEA HD from pivotal PULSAR trial demonstrated durable vision gains at extended dosing intervals in wAMDFDA accepted for priority review BLA for odronextamab for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) and sBLA for Dupixent in eosinophilic esophagitis (EoE) in children aged 1 to 11 years of ageAcquisition of Decibel Therapeutics completed, strengthening genetic medicines portfolio TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2023 and provided a business update. \"We have continued our momentum in the third quarter of 2023 with double-digit year-over-year revenue growth, driven by strong Dupixent and Libtayo performance, as well as strong initial uptake of EYLEA HD following its late August launch,\" said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. \"We are also making significant progress across our diversified pipeline, with FDA priority review designations for odronextamab in relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma as well as for Dupixent in pediatric eosinophilic esophagitis, while also adding a promising gene therapy platform to our portfolio through the recent acquisition of Decibel Therapeutics.\" Financial Highlights ($ in millions, except per share data) Q3 2023 Q3 2022 % Change Total revenues $3,363 $2,936 15% GAAP net income $1,008 $1,316 (23%) GAAP net income per share - diluted $8.89 $11.66 (24%) Non-GAAP net income(a) $1,329 $1,270 5% No...